Registry on Hypomethylating Agents in Myeloid Neoplasms

Arbeitsgemeinschaft medikamentoese Tumortherapie

Status: Completed

Conditions: Myelodysplastic Syndromes; Acute Myeloid Leukemia; Chronic Myelomonocytic Leukemia

Treatments: Other: non interventional

Study type: Observational

Funder types: Other

Identifiers

NCT01595295

AGMT_HMA Register

Details and patient eligibility

About

This registry is set up to collect real-world experience in the management of patients with myeloid neoplasms, in particularly in patients with MDS, CMML or AML, treated with hypomethylating agents in Austria and potentially other participating countries. This registry will collect data in a retrospective as well as in a prospective manner at various sites. The aim is to gain valuable insights on both efficacy and toxicity of these drugs in a routine clinical setting in patients with various comorbidities.

Enrollment: 1,500 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

Patients with MDS, CMML, and AML

• who begin with or already have received treatment with with a hypomethylating agent
• who are willing to provide informed consent

Exclusion criteria

• Due to the non-interventional design of this program there are no specific exclusion criteria.

Trial design

1,500 participants in 1 patient group

Hypomethylating Agents

Description:

Patients treated with hypomethylating agents

Treatment:

Other: non interventional